The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Different efficacy of pembrolizumab in overall survival between Asians and non-Asians with advanced cancers: A systematic review and meta-regression analysis.
 
Shang-Hsuan Peng
No Relationships to Disclose
 
Ching-Hung Lin
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer
 
I-Chun Chen
No Relationships to Disclose
 
Ying-Chun Shen
No Relationships to Disclose
 
Dwan-Ying Chang
No Relationships to Disclose
 
Tom Wei-Wu Chen
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Roche
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai; Roche
 
Shu-Min Huang
No Relationships to Disclose
 
Fu-Chang Hu
No Relationships to Disclose
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis